在中低收入国家开发新型 mRNA 候选疫苗的关键考虑因素：世界卫生组织/药物专利池 mRNA 技术转让计划会议报告。
Key considerations for the development of novel mRNA candidate vaccines in LMICs: A WHO/MPP mRNA Technology Transfer Programme meeting report.
机构信息
World Health Organization, Geneva, Switzerland.
World Health Organization, Geneva, Switzerland.
出版信息
Vaccine. 2023 Nov 30;41(49):7307-7312. doi: 10.1016/j.vaccine.2023.10.027. Epub 2023 Nov 8.
The WHO/MPP mRNA Technology Transfer Programme, initiated in 2021, focuses on establishing mRNA vaccine manufacturing capacity in LMICs. On 17-21 April 2023, Programme partners were convened to review technology transfer progress, discuss sustainability aspects and promote mRNA product development for diseases relevant to LMICs. To help guide product development, this report introduces key considerations for for understanding the likelihood of technical and regulatory success and of policy development and procurement for mRNA vaccines to be developed and manufactured in LMICs. The report underscores the potential for LMICs to establish sustainable mRNA R&D pipelines.
世界卫生组织/药品专利池组织 mRNA 技术转让计划于 2021 年启动，专注于在中低收入国家建立 mRNA 疫苗生产能力。2023 年 4 月 17 日至 21 日，计划合作伙伴举行会议，审查技术转让进展，讨论可持续性问题，并推动为中低收入国家相关疾病开发 mRNA 产品。为帮助指导产品开发，本报告介绍了一些关键考虑因素，以了解在中低收入国家开发和制造的 mRNA 疫苗在技术和监管方面取得成功的可能性，以及政策制定和采购的可能性。报告强调了中低收入国家建立可持续 mRNA 研发管道的潜力。
Zotero 插件